UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 14, 2003
Date of Report (date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 0-23272 | 87-0439579 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
420 Chipeta Way
Salt Lake City, Utah 84108
(Address of principal executive offices)
(801) 583-4939
(Registrant’s telephone number, including area code)
ITEM 7: Financial Statements and Exhibits
(c) | Exhibits | |||
Exhibit | Description | |||
99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on May 14, 2003 announcing the Company’s first quarter 2003 financial results. |
ITEM 9: Regulation FD Disclosure (Information below is also being filed under Item 12)
In accordance with SEC Release No. 33-8216, the following information, which is intended to be furnished under Item 12, “Results of Operations and Financial Condition,” is instead being furnished under Item 9, “Regulation FD Disclosure.” On May 14, 2003, NPS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s first quarter 2003 financial results. The text of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 14, 2003 | NPS PHARMACEUTICALS, INC. | |||
By: | /s/ HUNTER JACKSON | |||
Hunter Jackson CEO, President and Chairman of the Board |
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on May 14, 2003 announcing the Company’s first quarter 2003 financial results. |